BioAge Labs, Inc. BIOA R2K
Company Overview
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue +91.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | 91.00% |
Stock Price Performance
| 1 Year: | +392.01% |
| 6 Months: | +62.37% |
| 3 Months: | +40.70% |
| 1 Month: | +38.48% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)54.14 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BIOA BioAge Labs, Inc. R2K | 22.78 | -9.49 | $1.01B | 0.00% | -33.77% | -25.98% | - | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 0 | 0 | 1.45M | 2.41M | 2.05M | 2.77M |
| Operating Income | - | - | -9.89M | -12.81M | -15.27M | -24.75M | -16.45M | -24.77M | -23.14M | -25.38M |
| Net Income | -11.08M | -17.19M | -14.62M | -12.99M | -13.58M | -23.41M | -12.93M | -21.56M | -20.17M | -22.25M |
| Diluted EPS | - | - | -8.74 | -7.76 | -7.94 | -6.70 | -0.36 | -0.60 | -0.56 | -0.52 |
| R&D Expense | - | - | 6.53M | 9.32M | 10.47M | 20.02M | 11.11M | 19.84M | 18.51M | 20.41M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | - | 0 | 8.99M |
| Operating Income | -48.40M | -78.19M | -92.78M |
| Net Income | -63.85M | -71.11M | -80.61M |
| Diluted EPS | -38.17 | -6.63 | -2.24 |
| R&D Expense | 33.89M | 59.04M | 73.97M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | - | 25.92M | 358.23M | 294.89M |
| Total Equity | -112.56M | -173.40M | 323.13M | 272.05M |
| Cash & Equivalents | - | 21.64M | 354.35M | 188.89M |
| Long Term Debt | - | 8.20M | 2.50M | 0 |
| Total Liabilities | - | 66.60M | 35.11M | 22.84M |
| Current Liabilities | - | 58.17M | 27.77M | 20.14M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -37.36M | -51.52M | -81.63M |
| Investing Cash Flow | -266.00K | -366.00K | -95.22M |
| Financing Cash Flow | 34.94M | 381.20M | 11.47M |
| Capital Expenditure | -166.00K | -366.00K | -719.00K |
| Free Cash Flow | -37.53M | -51.89M | -82.35M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | - |
| Operating Margin % | - | - | -1,031.5% |
| Net Margin % | - | - | -896.1% |
| ROE % | 36.8% | -22.0% | -29.6% |
| ROCE % | 150.1% | -23.7% | -33.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | a16z Capital Management, L.L.C. | 7.27% | 3.23M | $81.93M |
| 2 | Cormorant Asset Management, LP | 6.50% | 2.89M | $73.25M |
| 3 | Sofinnova Investments, Inc. | 5.16% | 2.29M | $58.12M |
| 4 | Blackrock Inc. | 5.10% | 2.27M | $57.46M |
| 5 | Janus Henderson Group PLC | 4.71% | 2.09M | $53.07M |
| 6 | Octagon Capital Advisors LP | 3.93% | 1.75M | $44.29M |
| 7 | RA Capital Management, L.P. | 3.71% | 1.65M | $41.83M |
| 8 | Vanguard Capital Management LLC | 3.05% | 1.35M | $34.33M |
| 9 | Balyasny Asset Management LP | 2.99% | 1.33M | $33.64M |
| 10 | Braidwell LP | 2.70% | 1.20M | $30.42M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BIOA
More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented results from the real-world Lecanemab in Early Alzheimer's Disease (LEADER) Study showing that nearly 83% of patients with early Alzheimer's disease (AD) enrolle…
HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction
Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH), congratulates its partner BioAge Labs, Inc. ("BioAge"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic …
Is BioAge Labs, Inc. (BIOA) Stock Positioned for Growth With New Phase 2 Cardiovascular Study Initiation?
We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. BioAge Labs, Inc. (NASDAQ:BIOA) is one of the best low-priced pharma stocks on this list. TheFly reported on June 16 that BIOA announced the dosing of the…
BioAge Labs (BIOA) Is Up 14.2% After Starting Phase 2 Trial Of Oral NLRP3 Inhibitor
BioAge Labs has dosed the first participant in QUELL-CV, a 12-week, 160-patient Phase 2 proof-of-concept trial of its oral NLRP3 inhibitor BGE-102 in adults with obesity, elevated inflammation, and additional cardiovascular risk factors. An…
BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk
Randomized, double-blind, placebo-controlled, dose-ranging trial evaluating three once-daily oral doses of BGE-102 in participants with elevated systemic inflammation and additional cardiovascular risk factors Primary endpoint is percent ch…
BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease
BioAge Labs (NASDAQ:BIOA) executives used a fireside chat at the Jefferies 2026 Global Healthcare Conference to outline the company’s plans for BGE-102, its lead NLRP3 inhibitor, with near-term readouts expected in cardiovascular risk and d…
BIOA — Frequently Asked Questions
What is the current share price of BioAge Labs, Inc. (BIOA)?
As of 2026-07-14 21:23 PDT, BioAge Labs, Inc. (BIOA) trades at $22.78 on NasdaqGS. Its 52-week range is $4.12 to $25.10.
What is the market capitalisation of BIOA?
BioAge Labs, Inc. (BIOA) has a market capitalisation of $1.01B on NasdaqGS.
What is the P/E ratio of BIOA?
BIOA trades at a trailing price-to-earnings (P/E) ratio of -9.49. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 2.11.
What is the return on equity (ROE) of BIOA?
BIOA has a return on equity (ROE) of -25.98%. Its return on capital employed (ROCE) is -33.77%.
Is BIOA a good stock to buy?
This page provides a data-driven analysis of BioAge Labs, Inc. (BIOA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.